Search

Search Constraints

You searched for: Author/Creator Offner, Fritz

Search Results

11. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Issue 10020 (20th February 2016)

12. Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?. (22nd January 2022)

13. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Issue 10 (October 2021)

14. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Issue 13 (October 2015)

15. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM‐003 trial for pomalidomide plus low‐dose dexamethasone. (18th November 2014)

16. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM‐003 trial for pomalidomide plus low‐dose dexamethasone. (18th November 2014)

17. Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis. (26th November 2013)

18. Phase IA/II, multicentre, open‐label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non‐Hodgkin or Hodgkin lymphoma. (13th November 2013)

19. Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma. Issue 2 (10th February 2022)

20. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Issue 7 (July 2020)